EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Generative Artificial Intelligence and Predictive Analytics in Clinical Data Management: A Review of the Emerging Applications to Study Protocol Development and Case Report Form Design

Prasanna Kumar C S, PhD

Journal of the Society for Clinical Data Management · 2026-10-28 · 0 (1)

DOI: 10.47912/jscdm.499 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background: Clinical trial operations incur substantial costs from two preventable sources: protocol amendments — which affect more than 40% of studies and average $450,000 each in remediation expense — and Case Report Form (CRF) design deficiencies, which contribute to high data-query rates and prolonged database-lock timelines. Generative artificial intelligence (GenAI) and predictive analytics have attracted growing industry interest as tools that could address both problems systematically. Objectives: This review examines how GenAI and predictive analytics are currently being applied to clinical study protocol authoring, eligibility criteria optimisation, CRF design, and CDISC-compliance mapping; evaluates the evidence for operational improvement; and identifies unresolved technical, regulatory, and ethical challenges. Methods: A narrative synthesis was conducted using peer-reviewed literature (PubMed, Embase, Scopus, IEEE Xplore; 2019–2025), regulatory guidance documents (FDA, EMA, ICH), and relevant grey literature. Sources were assessed for methodological transparency and relevance to clinical data management practice. Results: Domain-adapted large language models reduced protocol authoring time by 30–45% and lowered first-draft amendment rates by up to 28% in reported implementations. AI-assisted CRF generation cut form-build timelines from weeks to under 72 hours and reduced data-query rates by 22–35%. Predictive analytics models demonstrated approximately 85% accuracy in prospective enrollment forecasting, and digital twin approaches provided statistical efficiency equivalent to a 25% sample-size reduction in selected Phase II scenarios. Conclusions: Evidence supports meaningful operational gains from AI integration in clinical data management workflows; however, prospective controlled evaluations remain scarce. Hallucination mitigation, bias-aware model governance, and alignment with evolving FDA and EMA guidance are prerequisites for responsible adoption.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →